Consequently, blocking PD-L2 with antibodies synergizes with chemotherapy to drive CD8 T cell-mediated tumor regression in pancreatic and mammary cancer models, offering a novel therapeutic strategy targeting therapy-induced senescence vulnerabilities [65]. Here, PDCD1LG2 is linked to neoplasm.